Survey of cyclosporine therapeutic ranges, assay methodology, and use of 'sparing agents' in Australasian transplant centers

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 650-656

  Jones, Terry E ^a   Morris, Raymond G ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cyclosporine; Sparing agent; Therapeutic monitoring

Indexed keywords

CYCLOSPORIN; DILTIAZEM;

ARTICLE; AUSTRALIA; DRUG DETERMINATION; DRUG MONITORING; DRUG UTILIZATION; GRAFT REJECTION; HEALTH SURVEY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; NEW ZEALAND; ORGAN TRANSPLANTATION; PRIORITY JOURNAL;

ADULT; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG MONITORING; HEALTH CARE SURVEYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEW ZEALAND; ORGAN TRANSPLANTATION; SUBSTANCE-RELATED DISORDERS;

EID: 0031439489     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00008     Document Type: Article

References (24)

1. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986;2(8505):523.
2. Kohlaw K, Wonigeit K, Frei U, Oldhafer K, Neuman K, Pichlmayr R. Effect of the calcium channel blocker diltiazem on cyclosporin A blood levels and dose requirements. Transplant Proc 1988;XX,2(suppl 2):572-4.
3. Valantine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 1992;11:1-8.
4. First RM, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991;51:365-70.
5. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporin after cardiac transplantation. N Eng J Med 1995;333:628-33.
6. Epstein M. Calcium Antagonists and Renal Protection. Arch Int Med 1992;152:1573-84.
7. Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith, P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993;55(2):300-4.
8. Vasquez EM, Pollak R. Effect of calcium channel blockers on graft outcome in cyclosporine-treated renal allograft recipients. Transplantation 1995;60(8):885-7.
9. Jones TE. Survey of cyclosporin sparing agent use in Australasian transplant centres. Aust NZ J Med 1996;26:772-6.
10. Wagner K, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplants by diltiazem. Lancet 1985;ii:1355-6.
11. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction. Lancet 1986;1:979.
12. Jones TE, Morris RG. Diltiazem does not always increase cyclosporin concentrations. Br J Clin Pharmacol 1996;42:642-4.
13. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992;33: 39-43.
14. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampicin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
15. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
16. Morris RG, Jones TE, Mathew TH. Formulation of diltiazem affects cyclosporin-sparing activity, Eur J Clin Pharmcol 1997;52:55-8.
17. Cooke CE. Nontherapeutic Cyclosporine Levels. Transplantation 1994;57(11):1687.
18. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation. Ther Drug Monit 1995;17(6):642-54.
19. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996;30(2):107-40.
20. Holt DW, Johnstone A, Roberts NB, Tredger JM, Trull AK. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994;31:420-46.
21. Dusci LJ, Hackett P, Chiswell GM, Illett KF. Comparison of cyclosporin in whole blood by high performance liquid chromatography, monoclonal fluorescentpolarization immunoassay and monoclonal enzyme multiplied immunoassay. Ther Drug Monit 1992;14:327-32.
22. Kunzendorf U, Brockmoller J, Jochimsen F, Roots I, Offermann G. Immunosuppressive properties of cyclosporin metabolites. Lancet 1989;1:734-5.
23. Jacqz-Agrain E, Montes C, Brun P, Loirat C. Cyclosporin pharmacokinetics in nephrotic and kidney transplanted children. Eur J Clin Pharmacol 1994;47:61-5.
24. Whittington PF, Edmond JC, Whittington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990;322:733-8.